with dyspepsia remains an important clinical issue.
There are both invasive and non-invasive methods available for detecting H. pylori infection. The invasive methods, including the Campylobacter-Iike organism (CLO) test, histological stain and culture for H. pylori, require endoscopy and often cause patient discomfort. In order to avoid endoscopy many non-invasive tools are used in patients without renal failure. These include serological IgG, urea breath test (UBT), and H. pylori-stool antigen assay (HpSA) (10) (11) (12) (13) . Among these non-invasive methods, UBT has proven to be a highly sensitive (>96%) and specific (>96%) diagnostic method for screening and monitoring the success of eradication therapy (10, 13, 14) . However, as the urease activity of H. pylori may be induced in ESRD patients by the prevailing higher level of urea in gastric aspirate or alternatively by the presence of another urease-producing organism, such as Proteus spp (15) , the prevalence of false positive UBT results increases in ESRD patients (9) . HD therapy can reduce the number of false positive results, possibly decreasing the urea level in the gastric aspirate. Accordingly, the specificity of UBT increases if the test is done after HD therapy (9) .
As the results of post-HD gas sampling were more reliable than those of pre-HD gas sampling, a more prolonged HD session may resolve the issue of poor specificity of 13C UBT in ESRD patients. However, despite performing UBT after HD therapy to prevent false positives, UBT for H. pylori detection is only 93.8% sensitive and 85.3% specific in ESRD patients (9) , which makes the test less accurate than in patients without renal function impairment. A more sensitive and specific noninvasive tool than UBT is thus needed to clinically detect the infection in ESRD patients.
In a large-scale screening study for H. pylori infection in ESRD patients, Wang et al confirmed that HpSA had 97.5% sensitivity and 97.5% specificity (16) . Also, HpSA achieved 100% sensitivity and more than 96% specificity in detecting failure of H. pylori eradication therapy in both the ESRD group and in non-uremic controls. These findings confirm that HpSA can be applied not only to screening for H. pylori infection, but also to monitoring the success of eradication therapy in ESRD patients. In contrast to the high diagnostic yield of HpSA, serologic IgG testing was less sensitive (87.5%) and specific (around 80%) for H. pylori screening in the ESRD group receiving HD. As HD patients may have been exposed to multiple blood transfusions, it is reasonable to expect that such an indirect detection of H. pylori-related antibody as IgG would be less effective than the direct antigen assay of HpSA. Considering that the decline of H. pylori-specific IgG in serum is usually slow and may take some time, Wang et al even found that testing for serum IgG was not suitable to monitor the success of H. pylori eradication (16) .
There are only limited reports of H. pylori eradication among ESRD patients (3, 16) . Wang et al compared the outcome of one-week proton-pump inhibitor-based triple therapy for H. pylori eradication between ESRD and nonuremic control groups (16) . In that study, the side effects were similar in the two groups, except that a metallic taste or bitterness of mouth was more commonly found in the It>Wichtig Editore, 2001 0391-3988/669-02 $01.00/0 ESRD patients. Eradication rate (near 90%) of patients with ESRD was as high as in the non-uremic group. Thus triple therapy is safe, usually well tolerated, and effective in eradicating H. pylori infection in patients already on dialysis (16) . In patients with impaired renal function not yet on dialysis, the safety of triple therapy deserves further study.
In brief, H. pylori infection is still an important pathogen causing peptic ulcers in ESRD patients receiving HD. The H. pylori stool antigen assay is more reliable than UBT to detect such infection non-invasively both for screening and for monitoring the success of therapy. Serologic IgG is less suitable for H. pylori screening in ESRD patients. Triple therapy is safe and highly effective for eradication in
